Search Results

Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS.

• Authors : Wang Z; Department of Thoracic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.; Su X

Subjects: Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/adverse effects ; Zoledronic Acid*/Zoledronic Acid*/Zoledronic Acid*/therapeutic use ; Adverse Drug Reaction Reporting Systems*

• Source: BMC cancer [BMC Cancer] 2024 Dec 18; Vol. 24 (1), pp. 1520. Date of Electronic Publication: 2024 Dec 18.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.

• Authors : Wang L; Department of General Surgery, Fuling Central Hospital of Chongqing City, Chongqing, China.; Fang D

Subjects: Bone Neoplasms/Bone Neoplasms/Bone Neoplasms/*drug therapy ; Bone Neoplasms/Bone Neoplasms/Bone Neoplasms/*secondary ; Osteoclasts/Osteoclasts/Osteoclasts/*cytology

• Source: BMC cancer [BMC Cancer] 2020 Nov 03; Vol. 20 (1), pp. 1059. Date of Electronic Publication: 2020 Nov 03.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.

• Authors : Watanabe D; Department of Palliative Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. .; Department of Urology, Koto Hospital, Tokyo, Japan. .

Subjects: Bone Density/Bone Density/Bone Density/*drug effects ; Bone Density Conservation Agents/Bone Density Conservation Agents/Bone Density Conservation Agents/*administration & dosage ; Prostatic Neoplasms/Prostatic Neoplasms/Prostatic Neoplasms/*epidemiology

• Source: BMC cancer [BMC Cancer] 2021 Apr 17; Vol. 21 (1), pp. 422. Date of Electronic Publication: 2021 Apr 17.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.

• Authors : Liu H; Department of Surgery, Chi Mei Medical Center, Liouying, Tainan, Taiwan.; Wang SH

Subjects: Immunologic Factors/Immunologic Factors/Immunologic Factors/*pharmacology ; T-Lymphocytes, Regulatory/T-Lymphocytes, Regulatory/T-Lymphocytes, Regulatory/*immunology ; Triple Negative Breast Neoplasms/Triple Negative Breast Neoplasms/Triple Negative Breast Neoplasms/*drug therapy

• Source: BMC cancer [BMC Cancer] 2019 Feb 26; Vol. 19 (1), pp. 176. Date of Electronic Publication: 2019 Feb 26.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.

• Authors : Li Y; Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.; Du Y

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Mammary Neoplasms, Experimental/Mammary Neoplasms, Experimental/Mammary Neoplasms, Experimental/*pathology

• Source: BMC cancer [BMC Cancer] 2018 Jun 19; Vol. 18 (1), pp. 669. Date of Electronic Publication: 2018 Jun 19.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.

• Authors : Göbel, Andy^1,2 (AUTHOR) ; Zinna, Valentina M.³ (AUTHOR); Dell'Endice, Stefania¹ (AUTHOR)

Subjects: *ZOLEDRONIC acid; *VASCULAR endothelial growth factors; *TRANSFORMING growth factors

• Source: BMC Cancer. 7/29/2020, Vol. 20 Issue 1, p1-17. 17p. 1 Chart, 6 Graphs.

Record details

Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.

• Authors : Odri, Guillaume^1,2,3; Pui-Pui Kim^1,2; Lamoureux, François^1,2

Subjects: *ZOLEDRONIC acid; *METASTASIS; *EWING'S sarcoma

• Source: BMC Cancer. 2014, Vol. 14 Issue 1, p1-9. 9p.

Record details

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.

• Authors : Banys, Malgorzata^1,2 ; Solomayer, Erich-Franz³ ; Gebauer, Gerhard²

Subjects: *ZOLEDRONIC acid; *CANCER cells; *BREAST cancer patients

• Source: BMC Cancer. 2013, Vol. 13 Issue 1, p1-21. 21p. 1 Diagram, 4 Charts, 3 Graphs.

Record details

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

• Authors : Harrer, Dennis C.^1,2; Simon, Bianca^1,3; Shin-ichiro Fujii⁴

Subjects: *CYTOPROTECTION; *ZOLEDRONIC acid; *RANDOMIZED controlled trials

• Source: BMC Cancer. 8/17/2017, Vol. 17 Issue 1, p1-17. 17p. 6 Graphs.

Record details

Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay

• Authors : Fehm, Tanja; Zwirner, Manfred; Wallwiener, Diethelm

• Source: BMC Cancer. July 23, 2012, Vol. 12

Record details